Back to Search
JONATHAN FORBES, M.D.
M.D.
Neurological Surgery Physician
NPI: 1609928084IndividualAccepts Medicare
Specialties, Licenses & Credentials
Surgery Physician
Surgery
Code: 208600000X
CA126321(CA)MD0000043868(TN)T1609(MD)
Neurological Surgery PhysicianPrimary
Neurological Surgery
Code: 207T00000X
35.132936(OH)
Education
UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE
Class of 2006
Research & Publications (20)
The use of early adjuvant aromatase inhibitor therapy: contributions from the BIG 1-98 letrozole trial.
PMID 16730270·Semin Oncol·2006
3-trial
Choosing between endocrine therapy and chemotherapy--or is there a role for combination therapy?
PMID 12353822·Breast Cancer Res Treat·2002
6-review
Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial.
PMID 19474112·Ann Oncol·2009
3-trial
The effect of salsalate on insulin action and glucose tolerance in obese non-diabetic patients: results of a randomised double-blind placebo-controlled study.
PMID 19104769·Diabetologia·2009
2-rct
c-Jun NH2-terminal kinase activity in subcutaneous adipose tissue but not nuclear factor-kappaB activity in peripheral blood mononuclear cells is an independent determinant of insulin resistance in healthy individuals.
PMID 19258436·Diabetes·2009
8-other
Nanomechanics of full-length nebulin: an elastic strain gauge in the skeletal muscle sarcomere.
PMID 19463013·Langmuir·2009
7-preclinical
Serum carboxymethyllysine concentrations are reduced in diabetic men with abdominal aortic aneurysms: Health In Men Study.
PMID 19628355·J Vasc Surg·2009
8-other
Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93.
PMID 18953651·Breast Cancer Res Treat·2009
4-observational
Interactions between advanced glycation end-products (AGE) and their receptors in the development and progression of diabetic nephropathy - are these receptors valid therapeutic targets.
PMID 19149535·Curr Drug Targets·2009
6-review
RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes.
PMID 19158353·J Am Soc Nephrol·2009
7-preclinical
High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus.
PMID 19349317·Circulation·2009
4-observational
Gastrointestinal fistulae in chronic granulomatous disease.
PMID 19436280·Am J Gastroenterol·2009
5-case
Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer.
PMID 19553291·Ann Oncol·2009
3-trial
A new perspective on therapeutic inhibition of advanced glycation in diabetic microvascular complications: common downstream endpoints achieved through disparate therapeutic approaches?
PMID 19556753·Am J Nephrol·2009
6-review
Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93.
PMID 18259856·Breast Cancer Res Treat·2009
4-observational
Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes.
PMID 18511846·Diabetes·2008
7-preclinical
Reproducibility of visual assessment on mammographic density.
PMID 17616811·Breast Cancer Res Treat·2008
8-other
Perinatal exposure to antiretroviral therapy is associated with increased blood mitochondrial DNA levels and decreased mitochondrial gene expression in infants.
PMID 18684095·J Infect Dis·2008
8-other
Cardiac inflammation associated with a Western diet is mediated via activation of RAGE by AGEs.
PMID 18477705·Am J Physiol Endocrinol Metab·2008
7-preclinical
Advanced glycation: implications in tissue damage and disease.
PMID 18473952·Protein Pept Lett·2008
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 222 PIEDMONT AVE
CINCINNATI, OH 45219 - Phone
- (513) 475-8990
Quick Facts
- NPI
- 1609928084
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 4
- Locations
- 1
- Years in Practice
- 20
- Publications
- 20
Are you this provider?
Claim Your Profile